Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Metabolix

Related MBLX
Metabolix Provides Update on Biopolymer Manufacturing Plans
UPDATE: Metabolix Reports Placement Deal with Investors to Raise $25M in Financing

In a report published Friday, Jefferies & Company reiterated its Hold rating on Metabolix (NASDAQ: MBLX), but slightly lowered its price target from $2.20 to $1.50.

Jefferies noted, “We expect the technology value of Metabolix's PHA IP to continue to be masked by uncertainty as to what economics it may be able to capture on manufacturing partnerships, as well as whether a step up in its cash burn will be required to move biochemical partnerships to commercialization. We reiterate our Hold rating.”

Metabolix closed on Thursday at $1.32.

Latest Ratings for MBLX

Jan 2015JefferiesMaintainsHold
Oct 2014JefferiesMaintainsHold
Mar 2014Ardour CapitalDowngradesAccumulateHold

View More Analyst Ratings for MBLX
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (MBLX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→